Aids treatment in Africa: The risk of antiretroviral resistance;Aids behandeling in Afrika: Het risico van antiretrovirale resistentie

Nederlands Tijdschrift voor Geneeskunde

Volumn 151, Issue 48, 2007, Pages 2666-2671

  Hamers, R L ^a   Schuurman, R ^b   Van Vugt, M ^a   Derdelinckx, I ^b   Rinke De Wit, T F ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; ARTICLE; DISEASE SURVEILLANCE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNOLOGICAL MONITORING; LONG TERM CARE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; RISK ASSESSMENT; TREATMENT OUTCOME; VIRUS RESISTANCE; VIRUS STRAIN; WORLD HEALTH ORGANIZATION; ANTIVIRAL RESISTANCE; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; REVIEW; RISK FACTOR;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AFRICA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; PATIENT COMPLIANCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 36849041506     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. AIDS epidemic update. December 2006. WHO-UNAIDS report. Genève: WHO; 2006.
2. Palella jr FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-60.
3. Treating 3 million by 2005: making it happen. WHO-UNAIDS report. Genève: WHO; 2003.
4. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report, April 2007. Genève: WHO; 2007.
5. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, 2006 revision. Genève: WHO; 2006.
6. Gill CJ, Hamer DH, Simon JL, Thea DM, Sabin LL. No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. AIDS. 2005;19:1243-9.
7. Gupta RK, Pillay D. HIV resistance and the developing world. Int J Antimicrob Agents. 2007;29:510-7.
8. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS. 2006;20:W13-23.
9. Johnson VA, Brun-Vezinet F, Clotet B, Kuritzkes DR, Pillay D, Schapiro JM, et al. Update of the drug resistance mutations in HIV-1. Fall 2006. Top HIV Med. 2006;14:125-30.
10. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 1999;353:2195-9.
11. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA. 2002;288:181-8.
12. Derdelinckx I, Laethem K van, Maes B, Schrooten Y, Wit S de, Florence E, et al. Current levels of drug resistance among therapy-naive HIV-infected patients have significant impact on treatment response. J Acquir Immune Defic Syndr. 2004;37:1664-6.
13. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration. ART Cohort Collaboration (ART-CC) Groups. Lancet. 2006;367:817-24.
14. Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, Cane P, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2006;3(12):e540 [onlinetijdschrift].
15. Katzenstein D. Diversity, drug resistance, and the epidemic of sub-type C HIV-1 in Africa. J Infect Dis. 2006;194(Suppl 1):S45-50.
16. Adjé-Touré C, Celestin B, Hanson D, Roels TH, Hertogs K, Larder B, et al. Prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS-Drug Access Initiative in Abidjan, Cote d'Ivoire. AIDS. 2003;17(Suppl 3):S23-9.
17. Vergne L, Malonga-Mouellet G, Mistoul I, Mavoungou R, Mansaray H, Peeters M, et al. Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries. J Acquir Immune Defic Syndr. 2002;29:165-8.
18. Weidle PJ, Downing R, Sozi C, Mwebaze R, Rukundo G, Malamba S, et al. Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative - Uganda. AIDS. 2003;17(Suppl 3):S39-48.
19. Bourgeois A, Laurent C, Mougnutou R, Nkoue N, Lactuock B, Ciaffi L, et al. Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon. Antivir Ther. 2005;10:335-41.
20. Vergne L, Kane CT, Laurent C, Diakhaté N, Gueye NF, Gueye PM, et al. Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy. AIDS. 2003;17(Suppl 3):S31-8.
21. Somi G, Kibuka T, Diallo K, Tuhuma T, Kassim S, Bennett D, et al. Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar Es Salaam, Tanzania. 14th Conference on Retroviruses and Opportunistic Infections, February 25-28, 2007. Los Angeles: 2007.
22. Bussmann H, Novitsky V, Wester W, Peter T, Masupu K, Gabaitiri L, et al. HIV-1 subtype C drug-resistance background among ARV-naive adults in Botswana. Antivir Chem Chemother. 2005;16:103-15.
23. Toni T, Masquelier B, Bonard D, Faure M, Huet C, Caumont A, et al. Primary HIV-1 drug resistance in Abidjan (Côte d'Ivoire): a genotypic and phenotypic study. Primo-CI/PAC-CI Study Group. AIDS. 2002;16:488-91.
24. Toni TD, Recordon-Pinson P, Minga A, Ekouevi D, Bonard D, Bequet L, et al. Presence of key drug resistance mutations in isolates from untreated patients of Abidjan, Côte d'Ivoire: ANRS 1257 study. AIDS Res Hum Retroviruses. 2003;19:713-7.
25. Vidal N, Mulanga C, Bazepeo SE, Mwamba JK, Tshimpaka J, Kashi M, et al. HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in the Democratic Republic of Congo (DRC). AIDS Res Hum Retroviruses. 2006;22:202-6.
26. Little SJ, May S, Hecht F, Markovitz M, Daar ES, Kaldor J, et al. Increase in transmitted NNRTI drug resistance among recently HIV infected patients from North America and Australia. Antivir Ther. 2006;11:S110.
27. Ross LL, Florance A, Wine B, Craig C, Vavro C, McClernon D, et al. Prevalence of HIV-1 drug resistance-associated mutations in a large cohort of antiretroviral therapy (ART) naive HIV-infected individuals in the United States from 2000-2004. Antivir Ther. 2006;11:S120.
28. Wensing AM, Vijver DA van de, Angarano G, Asjö B, Balotta C, Boeri E, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005;192:958-66.
29. Blower S, Bodine E, Kahn J, McFarland W. The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS. 2005;19:1-14.
30. Bertagnolio S, Sutherland D. WHO approach to track HIV drug resistance emergence and transmission in countries scaling up HIV treatment. AIDS. 2005;19:1329-30.